Hospital
Ohiohealth Morrow County Hospital, INC.
Ohiohealth Morrow County Hospital, INC. was paid $3.75M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoOHIOHEALTH MORROW COUNTY HOSPITAL, INC.
MOUNT GILEAD, OH 43338
MOUNT GILEAD, OH 43338
33aNPI1790775161assigned 10/26/2005
33bProvider typeCritical Access Hospital
28Total paid$3.75M
24GClaims94,282
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#20 of 26
Median peer was paid$5.33M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,352 | $345K | |
| 2019 | 7,588 | $249K | |
| 2020 | 4,743 | $193K | |
| 2021 | 5,158 | $258K | |
| 2022 | 6,323 | $345K | |
| 2023 | 34,281 | $1.28M | |
| 2024incomplete | 23,837 | $1.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 9,736 | 9,114 | $1.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 5,066 | 4,625 | $579K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.9% | 3,446 | 808 | $298K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 1,802 | 1,615 | $213K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.2% | 738 | 482 | $195K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.3% | 2,488 | 2,186 | $161K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.9% | 1,360 | 1,144 | $146K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.5% | 421 | 350 | $130K |
| 80053 | Comprehensive metabolic panel | 2.2% | 6,937 | 5,888 | $82K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.1% | 2,073 | 1,909 | $77K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 291 | 259 | $75K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.8% | 757 | 497 | $67K |
85 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 1,267 | $46K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 131 | $43K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 1,177 | $42K |
| 80061 | Lipid panel | 1.1% | 1,589 | $41K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 1,799 | $40K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,826 | $36K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 978 | $29K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,382 | $28K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,543 | $24K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 110 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,508 | $23K |
| 85027 | <1% | 1,723 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,962 | $19K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 218 | $19K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 626 | $18K |
| 82607 | <1% | 507 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,401 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 542 | $12K |
| 73630 | <1% | 265 | $11K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,239 | $9K |
| 73130 | <1% | 218 | $9K | |
| 97161 | <1% | 295 | $9K | |
| 73610 | <1% | 191 | $8K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 91 | $7K |
| 84439 | <1% | 246 | $6K | |
| 82728 | <1% | 319 | $6K | |
| 81001 | <1% | 1,795 | $6K | |
| 73030 | <1% | 134 | $5K | |
| 83540 | <1% | 469 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 124 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 35 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 134 | $5K |
| 71271 | <1% | 14 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,179 | $5K |
| 84153 | <1% | 204 | $4K | |
| 84484 | <1% | 1,218 | $4K | |
| 83550 | <1% | 462 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 83 | $4K |
| 87077 | <1% | 307 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $3K |
| 82570 | <1% | 243 | $3K | |
| 85610 | <1% | 976 | $3K | |
| 81003 | <1% | 3,157 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 115 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 82 | $2K |
| 87088 | <1% | 285 | $2K | |
| 73110 | <1% | 29 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $2K |
| 0011A | <1% | 59 | $1K | |
| 97162 | <1% | 12 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 54 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,216 | $1K |
| 83690 | <1% | 732 | $1K | |
| 82043 | <1% | 126 | $991.64 | |
| 83735 | <1% | 177 | $832.32 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 123 | $789.05 |
| 72100 | <1% | 12 | $749.39 | |
| 83880 | <1% | 67 | $575.52 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,222 | $563.77 |
| 82746 | <1% | 31 | $409.08 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 707 | $388.74 |
| 81025 | <1% | 675 | $381.10 | |
| 80320 | <1% | 12 | $344.77 | |
| 85730 | <1% | 742 | $259.30 | |
| 82248 | <1% | 61 | $239.25 | |
| 85652 | <1% | 36 | $170.52 | |
| 73502 | <1% | 13 | $151.53 | |
| 85379 | <1% | 80 | $132.77 | |
| 87081 | <1% | 24 | $130.55 | |
| 87040 | <1% | 35 | $128.97 | |
| 83605 | <1% | 57 | $123.71 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 27 | $93.74 |
| 82150 | <1% | 142 | $76.57 | |
| 87420 | <1% | 26 | $67.42 | |
| 80047 | <1% | 39 | $40.58 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 849 | $26.56 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 49 | $17.75 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 167 | $16.19 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 885 | $1.97 |
| 91301 | <1% | 60 | $0.43 | |
| 94664 | 0% | 153 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 131 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 34 | $0.00 |
| 96376 | 0% | 44 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGATES, JASON (DIRECTOR OF FINANCE/CONTROLLER)
| Provider | Location | Paid |
|---|---|---|
| Gates Eye Care Center, INC. | Newport, AR | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.